BackTheravance Biopharma Overview

Theravance Biopharma Receivables

Theravance Biopharma's receivables is $0.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00

Peer average

Loading

Theravance Biopharma Receivables History

Loading

Theravance Biopharma vs. peers: Receivables Comparison

Loading

Theravance Biopharma Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Theravance Biopharma (TBPH) FAQ

As of the most recent data (March 2026), TBPH shows a receivables of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, TBPH's receivables is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Theravance Biopharma is outperforming or lagging.

Tracking TBPH's receivables over time shows whether Theravance Biopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Theravance Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $0) with ownership activity and broader fundamentals.

Theravance Biopharma's receivables is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.